• 1
    Deplanque G, Harris AL. Anti-angiogenic agents: clinical trial design and therapies in development. Eur J Cancer 2000; 36: 171324.
  • 2
    Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet 2001; 2: 27889.
  • 3
    Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990; 50: 553742.
  • 4
    Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 1438.
  • 5
    Baguley BC. Small-molecule cytokine inducers causing tumor necrosis. Curr Opin Investig Drugs 2001; 2: 96775.
  • 6
    Galbraith SM, Lodge MA, Taylor NJ, Maxwell RJ, Tozer GM, Prise VE, Wilson J, Sens L, Robbins A, Padhani A, Rustin G. Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man. In: 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, May 12–15 2001.
  • 7
    Rosen MA, Englander S, Stevenson J, O'Dwyer PB, Schnall M. Dynamic gadolinium-enhanced MRI of tumors: effects of CA4P on tumor blood flow. In: 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, May 12–15 2001.
  • 8
    Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 182934.
  • 9
    Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999; 81: 131827.
  • 10
    Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001; 21: 93102.
  • 11
    Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 20609.
  • 12
    Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as vascular targeting agents. Int J Exp Pathology 2002; 83: 2138.
  • 13
    Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42: 899903.
  • 14
    Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59: 162634.
  • 15
    Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83: 8116.
  • 16
    Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001; 60: 15561.
  • 17
    Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61: 68115.
  • 18
    Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 18995.
  • 19
    Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, Overgaard J. Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000; 476: 31123.
  • 20
    Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5- fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20: 22933.
  • 21
    Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2000; 8: 15760.
  • 22
    Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001; 61: 471622.
  • 23
    Hill SA, Collingridge DR, Vojnovic B, Chaplin DJ. Tumour radiosensitization by high-oxygen-content gases: influence of the carbon-dioxide content of the inspired gas on pO2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys 1998; 40: 94351.
  • 24
    Smith KA, Hill SA, Begg AC, Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 1988; 57: 24753.
  • 25
    Chalkley HW. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst 1943; 4: 4753.
  • 26
    Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195204.
  • 27
    Korbelik M, Parkins CS, Shibuya H, Cecic I, Stratford MR, Chaplin DJ. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer 2000; 82: 183543.
  • 28
    Bohle AS, Leuschner I, Kalthoff H, Henne-Bruns D. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer 2000; 87: 83843.
  • 29
    Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs 2000; 11: 38592.
  • 30
    Rustin GJS, Price P, Stratford MRL, Galbraith SM, Anderson H, Folkes L, Robbins A, Sena L. Phase I study of weekly intravenous combretastatin A4 phosphate (CA4P): pharmacokinetics and toxicity. In: 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, May 12–15 2001.
  • 31
    Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 4827.
  • 32
    Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 9: 13204.
  • 33
    Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995; 63: 11923.
  • 34
    Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by non-toxic doses of vinblastine. Blood 1999; 94: 414355.
  • 35
    Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15R24.
  • 36
    Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 18439.
  • 37
    Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4: 13316.
  • 38
    O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5: 1817.
  • 39
    Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O-Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 187886.
  • 40
    Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman D, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 336972.
  • 41
    Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001; 71: 165765.
  • 42
    Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 2001; 12: 5763.